Grade 3 Colon Obstruction, CTCAE

MedGen UID:: 324198
•Concept ID:: C1556542
•: Finding

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVGrade 3 Colon Obstruction, CTCAE

Finding by Cause
- Adverse Event
  - Adverse Event by CTCAE Category
    - Adverse Event Associated with the Gastrointestinal System
      - Gastrointestinal Obstruction, CTCAE
        Colon Obstruction, CTCAE
        Grade 3 Colon Obstruction, CTCAE

Recent clinical studies

Etiology

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK)
Cancer Immunol Immunother 2021 May;70(5):1255-1262. Epub 2020 Nov 1 doi: 10.1007/s00262-020-02757-8. PMID: 33130956 Free PMC Article

See all (1)

Therapy

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

See all (1)

Clinical prediction guides

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

See all (1)

MedGen

National Center for Biotechnology Information

Send to:

Grade 3 Colon Obstruction, CTCAE

Term Hierarchy

Recent clinical studies

Etiology

Therapy

Clinical prediction guides

Supplemental Content

Table of contents

Recent activity